American Society of Hirudotherapy

Using metabarcoding to compare the suitability of two blood-feeding leech species for sampling mammalian diversity in North Borneo

Research article published in Molecular ecology resources (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyDrug DevelopmentDrinkwater R et al. · Molecular ecology resources, 2018

Abstract

The application of high-throughput sequencing (HTS) for metabarcoding of mixed samples offers new opportunities in conservation biology. Recently, the successful detection of prey DNA from the guts of leeches has raised the possibility that these, and other blood-feeding invertebrates, might serve as useful samplers of mammals. Yet little is known about whether sympatric leech species differ in their feeding preferences, and whether this has a bearing on their relative suitability for monitoring local mammalian diversity. To address these questions, we collected spatially matched samples of two congeneric leech species Haemadipsa picta and Haemadipsa sumatrana from lowland rainforest in Borneo. For each species, we pooled ~500 leeches into batches of 10 individuals, performed PCR to target a section of the mammalian 16S rRNA locus and undertook sequencing of amplicon libraries using an Illumina MiSeq. In total, we identified sequences from 14 mammalian genera, spanning nine families and five orders. We found greater numbers of detections, and higher diversity of OTUs, in H. picta compared with H. sumatrana, with rodents only present in the former leech species. However, comparison of samples from across the landscape revealed no significant difference in mammal community composition between the leech species. We therefore suggest that H. picta is the more suitable iDNA sampler in this degraded Bornean forest. We conclude that the choice of invertebrate sampler can influence the detectability of different mammal groups and that this should be accounted for when designing iDNA studies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAnimalsBorneoCluster AnalysisDNA Barcoding, TaxonomicDNA, RibosomalFeeding BehaviorHigh-Throughput Nucleotide SequencingHost SpecificityLeechesMetagenomicsPhylogenyRNA, Ribosomal, 16S

Summary

Peer-reviewed research on therapeutic compound development relevant to leech-derived anticoagulants and antithrombotic agents. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This field study collected spatially matched samples of two congeneric terrestrial leech species (Haemadipsa picta and H. sumatrana) from lowland rainforest in Borneo, pooled roughly 500 leeches per species into batches of 10, and used Illumina MiSeq metabarcoding of a mammalian 16S rRNA segment from their bloodmeals to detect sequences from 14 mammalian genera (nine families, five orders), finding more detections and higher OTU diversity (including rodents, present only in H. picta) and concluding H. picta is the more suitable invertebrate-derived-DNA (iDNA) sampler in this degraded forest. It is relevant to hirudotherapy chiefly as a window onto leech biology and host-feeding behavior, and as a reminder that blood-feeding leeches ingest and retain host material, which is conceptually pertinent to bloodborne-pathogen considerations in clinical leech use. Caveat: this is a biodiversity/conservation methods study of wild jungle leeches, not the medicinal species Hirudo medicinalis and not a clinical study; it has no bearing on therapeutic efficacy or patient safety and is purely contextual.

Citation

Using metabarcoding to compare the suitability of two blood-feeding leech species for sampling mammalian diversity in North Borneo.

Drinkwater R et al. · Molecular ecology resources, 2018

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.